Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
P/E ratio for Ipca Laboratories Limited (IPCALAB.NS)
P/E ratio as of 2023: 57.52
According to Ipca Laboratories Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 57.52. At the end of 2022 the company had a P/E ratio of 43.62.
P/E ratio history for Ipca Laboratories Limited from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 57.52 |
| 2022 | 43.62 |
| 2021 | 30.58 |
| 2020 | 21.15 |
| 2019 | 29.01 |
| 2018 | 27.63 |
| 2017 | 35.05 |
| 2016 | 38.82 |
| 2015 | 75.95 |
| 2014 | 30.96 |
| 2013 | 22.30 |
| 2012 | 20.46 |
| 2011 | 15.25 |
| 2010 | 14.34 |
| 2009 | 16.37 |
| 2008 | 8.23 |
| 2007 | 11.36 |
| 2006 | 11.92 |
| 2005 | 14.26 |
| 2004 | 10.13 |